


# LTL-427 datasheet

<b>Origin</b>	Primary human ovarian cancer	<b>Histopathology</b>	Serous adenocarcinoma
<b>Year of establishment</b>	2013	<b>Doubling time</b>	24 days (subrenal capsule grafting site)
<b>Local invasion</b>	Yes	<b>Metastasis</b>	Yes

The LTL-427 was developed from a patient's primary ovarian cancer (high grade serous carcinoma). When grafted under the renal capsules of SCID mice, the LTL-427 shows local invasion and distant metastases. The LTL-427 grows well subcutaneously. Viable tissues in early generations have been preserved following by cryopreservation (DMSO), and can be readily resurrected for grafting.



## H&E stained LTL-427 tissue sections

(A), the tumor cells grow in small nests or solid sheets (200x). (B), lung metastases (400x)

## Genetic and epigenetic characteristics

Tissue microarray containing LTL427 are in place for screening potential targets upon request.

## Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of mechanisms underlying tumor growth, progression and metastasis.

For more information, please contact us by email: [LTL@bccrc.ca](mailto:LTL@bccrc.ca) or phone: (604) 675 8013